E Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History

E Fund Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,482	Closed	-$141K	–	342
2022 Q2	$141K	Buy	12,482 +10,735	+614%	+$216K	0.01%	313
2022 Q1	$52K	Buy	1,747 +140	+9%	+$3.79K	﹤0.01%	322
2021 Q4	$43K	Sell	1,607 -48	-3%	-$1.45K	﹤0.01%	297
2021 Q3	$60K	Buy	+1,655	New	+$65.1K	﹤0.01%	266
2021 Q1	$89K	Buy	+2,603	New	+$103K	0.01%	245

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

E Fund Management's RIGL Position: Q3 2022 in Review

E Fund Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 12,482 shares — an estimated $141K sold.

E Fund Management first reported a position in RIGL in Q1 2021 and held it in 5 quarters. The position peaked at $141K in Q2 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

E Fund Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
E Fund Management sold 12,482 Rigel Pharmaceuticals shares in Q3 2022, an estimated $141K.
E Fund Management first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 5 quarters.
E Fund Management's Rigel Pharmaceuticals position peaked at $141K in Q2 2022.
138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on E Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.